-
艾媒报告 |2019中国基因测序产业研究和商业应用分析报告
本报告研究涉及企业/品牌/案例:Thermo Fisher(美),Illuminate(美),(瑞士),Stem cells(加),R&D(瑞士),华大基因,贝瑞基因,金城检验,美吉生物,恒创基因,基研生物,谱元科技,景杰生物,燃石生物,基迪奥生物,谷和信息,圣庭生物,天昊生物,诺禾致源,百迈克生物,思博奥科,赛莱拉,赛贝、北昊干细胞,达安基因,燃石医学、泛生子基因、世和基因,臻和生物,鹍远基因,23魔方,瀚海基因,百奥赛图,克睿基因,药明明码,裕策生物
随着基因测序的技术推进,基因测序开始应用于生物、侦查、无创产前检测和肿瘤治疗等场景中。技术的市场化应用吸引了全球资本方关注,iiMedia Research(艾媒咨询)数据显示,2018年全球医疗健康领域资本市场中,生物技术领域获得309件投资案共138亿元美元,领跑所有细分领域。中国生物技术科研研发实力厚积薄发,特别是科创板推动了基因测序市场的进一步升温,越来越多的生物创业公司在创业初期已获得高额融资。目前,中国已经基本形成了完整的上中下游产业链,但除了华大基因、贝瑞基因等少数头部企业,中国基因测序企业多数分布于产业链中下游,并且开始出现产品同质化等问题。艾媒咨询分析师认为,第二代测序技术的普及以及第三代测序技术的加紧研发将使得基因测序作为一个更加普遍的技术手段应用到不同场景之中,但目前仍然存在监管体系不够完善、道德伦理风险等问题。企业方面应当专注研究核心技术专利,通过人才储备和差异化竞争获得市场优势;行业和相关部门应当尽快完善行业规范管理体系,推动产业健康发展。
With the advancement of gene sequencing technology, gene sequencing began to be used in biological, detection, noninvasive prenatal testing and tumor treatment and other scenarios. The market-oriented application of technology has attracted global capital attention, with iiMedia Research leading all segments of the world in 309 investments in the global healthcare capital markets in 2018, with 309 investments, according to iiMedia Research. China's biotechnology research and development strength thick and thin hair, especially the science and technology board to promote the gene sequencing market further heating up, more and more bio-startup companies in the early stage of the start-up has been high financing. At present, China has basically formed a complete upstream and downstream industrial chain, but in addition to Huada gene, Berry gene and a few other head enterprises, Most of China's gene sequencing enterprises are distributed in the middle and lower reaches of the industrial chain, and began to appear product homogenization and other issues. Ai media consulting analysts believe that the popularity of second-generation sequencing technology and the third generation of sequencing technology will make gene sequencing as a more common technical means to apply to different scenarios, but there are still problems such as inadequate regulatory system, ethical risks. Enterprises should focus on researching core technology patents and gain market advantages through talent pool and differentiated competition, and industries and related departments should improve the industry standard management system as soon as possible to promote the healthy development of the industry. -
艾媒报告 |2019中国人造肉产业研究与消费者行为调查报告
本报告研究涉及企业/品牌/案例:Beyond Meat,Impossible Foods,杜邦,Ripple Foods,Bolthouse Farms,Roquette,Field Roast,Gardein,Mosa Meat,Modern Meadow,Finless Foods,烟台双塔食品,深圳齐善食品,宁波素莲素食,江苏鸿旭食品,万达财富,来伊份,登海种业,大北农,新开疆,京粮控股,四环生物,九芝堂,ST天宝,友好集团,爱普股份,丰乐种业,北大荒,天士力,中源协和,大康农业,东宝生物,融捷健康,华宝股份,戴维医疗,千红制药,金健米业,圣济堂,济民制药,哈高科,国际医学,维维股份,海欣食品,复星医药,苏常柴A,瑞茂通
人造肉主要包括植物肉、培育肉和混合肉三类。随着全球肉类短缺危机、健康与环保的消费风潮、食品创新推动等因素带动人造肉产业发展,资本市场开始关注人造肉产业,例如,Beyond Meat上市股市表现良好,Impossible Foods已完成超过6.875亿美元的多轮融资。中国的人造肉市场也开始发展,艾媒商情舆情数据监测系统显示,广东网民最关注人造肉议题。在资本和舆论的带动下,A股市场人造肉版块的活跃,同时,各类人造肉的上游产业链如大豆、豌豆蛋白、胎牛血清等开始共同发展。iiMedia Research(艾媒咨询),36%的中国消费者并不了解人造肉,同时低于四成消费者愿意尝试人造肉。艾媒咨询分析师认为,人造肉要真正市场化普及仍需克服成本、技术、消费者心理因素等多重障碍。
Artificial meat mainly includes three types of plant meat, cultivated meat and mixed meat. With the global meat shortage crisis, the consumption trend of health and environmental protection, and the promotion of food innovation, the capital market has begun to focus on the artificial meat industry. For example, Beyond Meat listed stocks performed well, and Impossible Foods has completed more than 687.5 million. Multiple rounds of financing for the dollar. China's artificial meat market has also begun to develop, and the iiMedia Research business data analysis system shows that Guangdong netizens are most concerned about artificial meat issues. Driven by capital and public opinion, the artificial meat section of the A-share market is active. At the same time, the upstream industrial chains of various types of artificial meat, such as soybean, pea protein and fetal bovine serum, have begun to develop together. iiMedia Research, 36% of Chinese consumers do not know about artificial meat, and less than 40% of consumers are willing to try artificial meat. Ai Media Consulting analysts believe that the real marketization of artificial meat still needs to overcome multiple obstacles such as cost, technology and consumer psychological factors. -
艾媒报告|2019中国婴幼儿保育行业细分领域深度分析报告
本报告研究涉及企业/品牌/案例:华润万家、Ekoala、美国费雪公司、长春长生生物科技股份有限公司、拉克塔利斯集团、帮宝适、好奇、妙而舒、大王、MOONY、妈咪宝贝、安儿乐、雀氏、茵茵、爹地宝贝、露安适、DODIE、凯儿得乐、倍康、米菲、吉氏、一朵、纽诺教育、馨心教育、圣顿教育、袋鼠麻麻、多乐小熊、Urjoy school
中国的婴幼儿保育行业主要包括婴幼儿食品、用品、医疗、托育等领域。在婴幼儿食品领域,2019年,中国婴幼儿的辅食渗透率仅为25.0%左右,中国大陆婴幼儿的辅食和奶粉消费额的比例为1:7,中国港澳台地区为1:4,欧美等发达国家为1:1。在婴童用品领域,2018年中国婴儿推车市场规模达到132.1亿元,同比增长6.3%。63.9%的消费者计划在2019年增加消费支出,其中22.0%的消费者预计消费支出增加比例超过三成。在婴幼儿医疗领域,2018年,共有28种药品被要求修改说明书,包括一些中药注射剂、中成药大品种等。在婴幼儿照护领域,2019年5月,中国国务院发布了《国务院办公厅关于促进3岁以下婴幼儿照护服务发展的指导意见》,提出要大力推动婴幼儿照护行业发展,而2019年中国3岁以下婴幼儿在各类托育机构的入托率仅为4.1%,远远低于发达国家25%-55%的入托率。
China's infant and children care industry mainly includes infant food, supplies, medical care, and childcare. In the field of infant food, in 2019, the penetration rate of complementary food for infants and young children in China was only about 25.0%. Meanwhile, the ratio of food supplement and milk powder consumption for infants and toddlers in mainland China is 1:7, while in developed countries (Europe and the United States, etc.), the ratio is 1:1, and that in Hong Kong, Macao and Taiwan is 1:4. In the field of baby products, the size of China's baby stroller market reached 13.21 billion yuan in 2018, a year-on-year increase of 6.3%. 63.9% of consumers plan to increase consumer spending in 2019, with 22.0% of them expecting a 30% increase in consumer spending. In the field of infant and child medical care, in 2018, a total of 28 kinds of medicines were required to modify the instructions, including some Chinese medicine injections and large varieties of proprietary Chinese medicines. In the field of infant care, in May 2019, the State Council of China issued the “Guiding Opinions of the General Office of the State Council on Promoting the Development of Infant and Child Care Services Under 3 Years Old”, proposing to vigorously promote the development of infant care industry. China’s infants and young children have a 4.1% enrollment rate in various types of care institutions, far lower than the enrollment rate of 25%-55% in developed countries. -
艾媒报告 |2019年中国生物医药产业发展及舆论焦点分析报告
本报告研究涉及企业/品牌包括:Takeda、GSK、Sanofi、Celgene、Novartis、宝洁、CVC Fund VII、Shire、诺华OTC、Bioverativ、Juno Therapeutics、AveXis、Impact Biomedicines、Tesaro、Ablynx、默克OTC、Recordati控股公司FIMEI、复星医药、海正药业、康弘药业、泰合健康、齐鲁制药、复宏汉霖、信达生物、张江生物、恒瑞医药、三生国健、嘉和生物、百奥泰、深圳龙瑞、天坛生物、华兰生物、博雅生物、上海莱士、卫光生物、辽宁成大、智飞生物、康泰生物、沃森生物、利德曼、交大昂立、华润双鹤、力生制药、海欣股份、联环药业、白云山、中源协和、普洛药业
随着生物医药技术不断突破,中国生物医药产业快速发展,2018年,单抗、血液制品、疫苗等生物医药相关领域多家头部上市企业营收均超亿元,实现同比增长。iiMedia Research(艾媒咨询)监测发现,生物医药产业网络言值指数为49.7,网民评价态度偏向正面,上海网民对生物医药产业的关注度最高。未来,随着中国生物医药行业上市公司数量增多,行业与企业间竞争将更加激烈。
The scale of China's bio-pharmaceutical industry continues to grow, and the proportion of bio-pharmaceutical output in the pharmaceutical industry continues to rise. In 2017, the total output value of the bio-pharmaceutical industry in China's park was about 1.5 trillion yuan. At present, China's biomedical industry has formed three major clusters, including the Bohai Rim region, the Yangtze River Delta region and the Pearl River Delta region, and the industrial agglomeration effect is outstanding. China's bio-pharmaceutical industry is in a stage of rapid development. In 2018, many head-to-head listed companies in biomedical related fields such as monoclonal antibodies, blood products and vaccines all exceeded 100 million yuan, achieving year-on-year growth. According to iiMedia Research, netizens in Shanghai are most concerned about the biomedical industry, and 40.9% of netizens surveyed support the application of transgenic technology in the pharmaceutical field. Among the heads of monoclonal antibodies, blood products and vaccines, Fuhong Hanlin as well as Weiguang Bio and Lidmanthe has the best online reputation,iiMedia Consulting analysts believe that in the future, the combination of artificial intelligence with new drug research and the fierce competition among head enterprises is an important trend in the development of China's biomedical industry.
没找到想要的报告?
扫码添加客服参与预约/定制,第一时间获取行业推荐报告!
智库热榜
艾媒咨询|2024-2025年中国银发经济投资前景分析报告
艾媒咨询|2024-2025年中国烘焙食品行业现状及趋势研究报告
艾媒咨询 | 2023-2024年中国休闲食品产业现状及消费行为数据研究报告
艾媒咨询|2024-2025年全球及中国新能源汽车行业消费趋势监测与案例研究报告
艾媒咨询 | 2023-2024年中国全域旅游产业运行数据及发展趋势研究报告
艾媒咨询 | 2024年中国家用美容仪行业消费者洞察研究报告
艾媒咨询|赵一鸣零食店消费行为洞察及行业趋势报告(2024)
艾媒咨询|2024年中国月饼行业创新发展研究报告
艾媒咨询 | 2024年中国数字中台市场研究报告
艾媒咨询|2023-2024年全球及中国跨境电商运营数据及典型企业分析研究报告
艾媒咨询|2024年中国家清产品消费趋势洞察报告